{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:10:49Z","timestamp":1767625849379,"version":"3.41.2"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis is a chronic inflammatory skin disease characterized by plaque formation. Interleukin (IL)\u201023 is upregulated in psoriatic lesions and is thought to be a major regulator of the Th17 pathway in psoriasis pathogenesis. Three monoclonal antibodies targeting the IL\u201023p19 subunit, guselkumab, tildrakizumab, and risankizumab, have been approved for psoriasis therapy. The balance between cytokines IL\u201023 and IL\u201012 can affect antitumor and pro\u2010tumor immune activities, and patients with psoriasis may have higher rates of cancer than the general population. Moreover, a chronic inflammatory state typical of psoriasis may induce protumorigenic effects, however, the potential risk of malignancy in patients taking these drugs remains largely unknown. This study investigated the occurrence of malignancies as suspected adverse reactions (SARs) potentially associated with IL\u201023 inhibitors by analyzing real\u2010world data from the European EudraVigilance database. Although indicatory, these real\u2010world data seem to confirm the potential association between the IL\u201023 inhibitors risankizumab and tildrakizumab, and the occurrence of SARs linked to cancer in patients with psoriasis and, according to a gender perspective, they show that this relationship is asymmetrically distributed between women and men, with a clear prevalence of oncologic SARs in men.<\/jats:p>","DOI":"10.1002\/prp2.1130","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:28:11Z","timestamp":1692872891000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Suspected oncologic adverse reactions associated with interleukin\u201023 inhibitors in <scp>EudraVigilance<\/scp>: Comparative study and gender distribution"],"prefix":"10.1002","volume":"11","author":[{"given":"Fabrizio","family":"Calapai","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine University of Messina  Messina Italy"},{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences University of Messina  Messina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Mannucci","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphological and Functional Imaging University of Messina  Messina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cardia","sequence":"additional","affiliation":[{"name":"Department of Human Pathology of Adult and Childhood \u201cGaetano Barresi\u201d University of Messina  Messina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariaconcetta","family":"Curr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine University of Messina  Messina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8116-4821","authenticated-orcid":false,"given":"Gioacchino","family":"Calapai","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences University of Messina  Messina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences University of Messina  Messina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Ammendolia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine University of Messina  Messina Italy"},{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences University of Messina  Messina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_11_2_1","DOI":"10.3390\/ijms20061475"},{"doi-asserted-by":"publisher","key":"e_1_2_11_3_1","DOI":"10.1038\/nm.3895"},{"doi-asserted-by":"publisher","key":"e_1_2_11_4_1","DOI":"10.2147\/CCID.S364640"},{"doi-asserted-by":"publisher","key":"e_1_2_11_5_1","DOI":"10.1007\/s40257-017-0337-2"},{"doi-asserted-by":"publisher","key":"e_1_2_11_6_1","DOI":"10.3389\/fonc.2021.687432"},{"doi-asserted-by":"publisher","key":"e_1_2_11_7_1","DOI":"10.1038\/s41598-022-18790-9"},{"doi-asserted-by":"publisher","key":"e_1_2_11_8_1","DOI":"10.1080\/09546634.2022.2133531"},{"doi-asserted-by":"publisher","key":"e_1_2_11_9_1","DOI":"10.3389\/fphar.2023.1091978"},{"issue":"175","key":"e_1_2_11_10_1","first-page":"247","article-title":"MedDRA and pharmacovigilance: a complex and little\u2010evaluated tool","volume":"25","year":"2016","journal-title":"Prescrire Int"},{"doi-asserted-by":"publisher","key":"e_1_2_11_11_1","DOI":"10.1002\/pds.1742"},{"doi-asserted-by":"publisher","key":"e_1_2_11_12_1","DOI":"10.1080\/1744666X.2020.1754194"},{"doi-asserted-by":"publisher","key":"e_1_2_11_13_1","DOI":"10.1007\/s00535-012-0620-1"},{"doi-asserted-by":"publisher","key":"e_1_2_11_14_1","DOI":"10.3389\/fimmu.2021.670398"},{"doi-asserted-by":"publisher","key":"e_1_2_11_15_1","DOI":"10.1016\/j.jaad.2010.04.046"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.1130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T07:42:53Z","timestamp":1697528573000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.1130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/prp2.1130"],"URL":"https:\/\/doi.org\/10.1002\/prp2.1130","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"type":"print","value":"2052-1707"},{"type":"electronic","value":"2052-1707"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"assertion":[{"value":"2023-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01130"}}